Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

Antibody therapeutics are a large and rapidly expanding drug class providing major health
benefits. We provide a snapshot of current antibody therapeutics including their formats …

BACKGROUND. CAR T cells are a promising therapy for hematologic malignancies. B cell
maturation antigen (BCMA) is a rational target in multiple myeloma (MM). METHODS. We …

Despite considerable advances in the treatment of multiple myeloma (MM) in the last
decade, a substantial proportion of patients do not respond to current therapies or have a …

Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …

Antibody-drug conjugates (ADCs) and immunotherapy have prompted a revolution in the
treatment of cancer. However, only a limited fraction of patients obtained a long-term benefit; …